Holen Sie sich die Stockscreener-App
21.81
1.02%
0.22
Handel nachbörslich:
21.81
Schlusskurs vom Vortag:
$21.59
Offen:
$21.79
24-Stunden-Volumen:
710.35K
Relative Volume:
0.60
Marktkapitalisierung:
$1.91B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-9.9589
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
-3.41%
1M Leistung:
+0.65%
6M Leistung:
-5.79%
1J Leistung:
-46.66%
1-Tages-Spanne:
$21.33
$22.34
1-Wochen-Bereich:
$21.33
$22.81
52-Wochen-Spanne:
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
21.81 | 1.98B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional
Is IDEAYA Biosciences Inc. a good long term investmentConsistent triple returns - Autocar Professional
IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan
What drives IDEAYA Biosciences Inc. stock priceExponential wealth increase - PrintWeekIndia
IDEAYA Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - jammulinksnews.com
What analysts say about IDEAYA Biosciences Inc. stockFree Stock Selection - jammulinksnews.com
(IDYA) Proactive Strategies - news.stocktradersdaily.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser
Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada
Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN
Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada
RBC Cuts Price Target on IDEAYA Biosciences to $30 From $57, Keeps Outperform, Speculative Risk - MarketScreener
Here's Why We're Watching IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - 富途牛牛
(IDYA) Long Term Investment Analysis - news.stocktradersdaily.com
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell Small Cap Comp Growth Index - MarketScreener
IDEAYA Biosciences: A Precision Oncology Play Gains Momentum with Russell 2000 Inclusion - AInvest
Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream - AInvest
IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year - AInvest
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Ideaya Biosciences shareholders elect directors and approve auditor at annual meeting - Investing.com
Rhumbline Advisers Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by GAMMA Investing LLC - Defense World
Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Comments on IDYA FY2026 Earnings - Defense World
Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by California State Teachers Retirement System - Defense World
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - PR Newswire
IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
IDEAYA Biosciences (IDYA) Grants Stock Options to New Employees | IDYA Stock News - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Nuveen Asset Management LLC - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $66.00 - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Consensus PT from Brokerages - Defense World
JP Morgan Raises Price Target for IDEAYA Biosciences (IDYA) | ID - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Ameriprise Financial Inc. - Defense World
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):